End-Stage Renal Disease and Economic Incentives: The International Study of Health Care Organization and Financing
73 Pages Posted: 27 Jun 2007 Last revised: 13 Nov 2022
Date Written: May 2007
Abstract
End-stage renal disease (ESRD), or kidney failure, is a debilitating, costly, and increasingly common medical condition. Little is known about how different financing approaches affect ESRD outcomes and delivery of care. This paper presents results from a comparative review of 12 countries with alternative models of incentives and benefits, collected under the International Study of Health Care Organization and Financing, a substudy within the Dialysis Outcomes and Practice Patterns Study. Variation in spending per ESRD patient is relatively small and is correlated with overall per capita health care spending. Between-country variations in spending are reduced using an input price parity index constructed for this study. Remaining differences in costs and outcomes do not seem strongly linked to differences in incentives embedded in national programs.
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Prescription Drugs, Medical Care, and Health Outcomes: A Model of Elderly Health Dynamics
By Zhou Yang, Donna B. Gilleskie, ...
-
Integrated Insurance Design in the Presence of Multiple Medical Technologies
By Dana P. Goldman and Tomas Philipson
-
Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits
By Martin Gaynor, Jian Li, ...
-
Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits
By Martin Gaynor, Jian Li, ...
-
By Amitabh Chandra, Jonathan Gruber, ...
-
By Avi Dor and William E. Encinosa
-
By William H. Crown, Ernst R. Berndt, ...
-
Prescription Drug Coverage and Elderly Medicare Spending
By Baoping Shang and Dana P. Goldman